Sponsor or institution
Clinical trials and research at Nuvation Bio Inc.
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Nuvation Bio Inc. that are recruiting, at sites in 4 countries (most in China (3), United States (3), Australia (1)). By phase: Phase 3 (3), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Safusidenib in IDH1-mutant glioma after vorasidenib progression | Phase 2 | Los Angeles, California and 11 other locations | Recruiting | Jul 14, 2026 |
| Taletrectinib versus placebo as adjuvant therapy for ROS1-positive early-stage non-small cell lung cancer | Phase 3 | Los Angeles, California and 32 other locations | Recruiting | Sep 4, 2025 |
| Comparing Taletrectinib with Standard Therapy for ROS1 Positive Lung Cancer | Phase 3 | Hefei, Anhui and 28 other locations | Recruiting | Aug 21, 2024 |
| Safusidenib as maintenance therapy for IDH1‑mutant astrocytoma and oligodendroglioma | Phase 3 | Birmingham, Alabama and 60 other locations | Recruiting | Mar 31, 2022 |
All recruiting trials (4)
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
-
Taletrectinib versus placebo as adjuvant therapy for ROS1-positive early-stage non-small cell lung cancer
This study will test whether taking taletrectinib after surgery can help prevent cancer from coming back in adults whose early-stage NSCLC tumors have a ROS1 fusion.
-
Comparing Taletrectinib with Standard Therapy for ROS1 Positive Lung Cancer
This study is testing if a new drug called Taletrectinib works better than the standard treatment Crizotinib for people with ROS1 positive lung cancer who haven't had treatment before.
-
Safusidenib as maintenance therapy for IDH1‑mutant astrocytoma and oligodendroglioma
This trial tests whether the oral drug safusidenib can help people with IDH1‑mutant astrocytomas or oligodendrogliomas remain progression‑free longer after surgery and standard radiation/chemotherapy.
Quick answers
How many clinical trials run by Nuvation Bio Inc. are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (3 trials), United States (3 trials), Australia (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.